Dermatology Times, June 2024 (Vol. 45. No. 06)

Learn more about the in-depth topics covered in the June 2024 print issue of Dermatology Times.

This month's Legal Eagle column explores if a dermatologist can be sued for charging a fee for providing medical records in a lawsuit.

From a financial perspective, the change from resident to attending dermatologist may be profound.

In this month's Cosmetic Conundrums column, Zoe Diana Draelos, MD, examines the most popular active ingredients in redness-reducing formulations.

Sara Osborne, a fourth-year medical student and the lead author on the study, spoke with Dermatology Times on key findings and explain the need for further investigation.

Although acne is common for most people to experience in their lifetime, it is important to individualize treatment and provide appropriate care when working with a diverse patient base.

To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.

Researchers hypothesize that skin contact with e-cigarette fluids can trigger an inflammatory response.

Step therapy can delay appropriate care and potentially worsen patients' conditions, writes Dermatology Times Spring Editor in Chief Aaron Farberg, MD.

Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.

The June issue of Dermatology Times features a collection of articles related to e-cigarette use and skin, Acne Awareness Month, and more.

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

Dermatology PAs and NPs continue to address the demand-supply mismatch in dermatologic care and can significantly bring their skills within the primary care model.

A poster from the 2024 American Psychiatric Association Annual Meeting delved into the relationship between MDD and various dermatologic conditions.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month and Melanoma Monday.

This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC.

A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.

In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.

Amy B. Lewis, MD, explores the evolution of aesthetic dermatology, delving into injection sophistication, devices, and top procedures.